ReviewJournal of cancer research and clinical oncology2026
Macrophage plasticity in the osteosarcoma tumor microenvironment: opportunities and challenges for immunotherapy.
Review in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering the malignant synergy: metabolic reprogramming, epigenetic circuitry, and niche remodeling in osteosarcoma-macrophage crosstalk.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Osteosarcoma is an aggressive primary malignancy bone tumor, characterized by a complex immune microenvironment, which poses significant challenges for immunotherapy. Tumor-associated macrophages (TAMs) are pivotal immune cells in the tumor microenvironment (TME), exhibiting remarkable plasticity, enabling them to switch between pro-tumorigenic and anti-tumorigenic phenotypes. Their functional polarization critically influences tumor progression and therapeutic response. This comprehensive review outlines the immune environment of osteosarcoma and the underlying mechanisms of macrophage plasticity. In this paper, we discuss the therapeutic possibilities through modulation of macrophages, their reprogramming and depletion, and the issues related to clinical translation. We describe how recent advances create an opportunity to target tumor-associated macrophages to improve patient responses. By synthesizing current knowledge on macrophage phenotypes, macrophage polarization, and preclinical-to-clinical therapeutic interventions, we present a strategic framework for development of macrophage-centric immunotherapies, highlighting a promising yet challenging avenue in improving patient outcome in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.